Search results for "PROGRESSION"

showing 10 items of 1251 documents

Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papil…

2019

Objectives: To investigate the expression of several immunohistochemical (IHC) markers and their predictive ability for the recurrence-free and progression-free survival of papillary urothelial bladder cancer (UBC) pTa/pT1 G2 (WHO 1973) compared to classical anatomo-clinical variables using a multidimensional analysis. Materials and Methods: A population-based cohort of 213 primary stage UBC (pTa/pT1) G2 (WHO 1973) was evaluated by classic anatomopathological variables and characterized by immunohistochemistry (23 IHC markers, representative of different oncogenic pathways). The most important variables as a predictor of recurrence-free and progression-free survival were selected using mult…

MaleOncologymedicine.medical_specialtyMultidimensional analysisSurvivinUrologyPopulation030232 urology & nephrologyCohort Studies03 medical and health sciences0302 clinical medicineCyclin D1Stage Ta/T1Predictive Value of TestsInternal medicineSurvivinBiomarkers TumormedicineHumansCyclin D1Progression-free survivalStage (cooking)educationCyclin-Dependent Kinase Inhibitor p16AgedNeoplasm Stagingeducation.field_of_studyBladder cancerbiologybusiness.industryClinical outcomeBladder cancerMiddle Agedmedicine.diseaseImmunohistochemistryCarcinoma PapillarySurvival RateKi-67 AntigenUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisKi-67biology.proteinImmunohistochemistryFemaleNeoplasm GradingNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy Speci…

2005

Abstract Purposes: To elucidate the prognostic value of the immunohistochemical (IHC) expression of Bcl-2, Bax, Cox-2 and Ki-67 antigen in biopsy cores (C) and surgical specimens (SP) of prostate cancer (PC) and to determine the C to SP reproducibility. Material and methods: The IHC study was carried out in 91 patients operated by means of radical prostatectomy (RP) with available formalin-fixed paraffin-embedded material from both C and SP. Results: The IHC expression of Bcl-2 in C and SP was very low (5%). Bax was expressed in almost all the patients and did not show any prognostic value. We observed a good reproducibility between C and SP for all molecules except with Bax. In prostate C,…

MaleOncologymedicine.medical_specialtyPathologyBiopsyUrologymedicine.medical_treatmentDisease-Free SurvivalProstate cancerProstateInternal medicineBiopsyBiomarkers TumormedicineHumansAgedRetrospective Studiesbcl-2-Associated X ProteinProstatectomyUnivariate analysismedicine.diagnostic_testbiologyProstatectomybusiness.industryMembrane ProteinsProstatic NeoplasmsAnatomical pathologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistryKi-67 Antigenmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2Cyclooxygenase 2Ki-67Multivariate AnalysisDisease Progressionbiology.proteinImmunohistochemistrybusinessEuropean Urology
researchProduct

A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma

2014

MaleOncologymedicine.medical_specialtyPoor prognosisSkin NeoplasmsHistologyMultivariate analysisMEDLINEPathology and Forensic MedicineText miningInternal medicinemedicineHumansIn patientMelanomaCD20biologybusiness.industryMelanomaDisease progressionGeneral MedicineAntigens CD20Prognosismedicine.diseaseMultivariate AnalysisDisease Progressionbiology.proteinFemalebusinessHistopathology
researchProduct

Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice

2021

Prostate cancer (PCa) is the most commonly diagnosed cancer in men. The diagnosis is currently based on PSA levels, which are associated with overdiagnosis and overtreatment. Moreover, most PCas are localized tumours; hence, many patients with low-/very low-risk PCa could benefit from active surveillance (AS) programs instead of more aggressive, active treatments. Heterogeneity within inclusion criteria and follow-up strategies are the main controversial issues that AS presently faces. Many biomarkers are currently under investigation in this setting; however, none has yet demonstrated enough diagnostic ability as an independent predictor of pathological or clinical progression. This work a…

MaleOncologymedicine.medical_specialtyQH301-705.5clinical biomarkers030232 urology & nephrologyReviewIndependent predictorCatalysisInorganic Chemistry03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineDaily practicemedicineHumansBiology (General)Physical and Theoretical ChemistryOverdiagnosisWatchful WaitingQD1-999Molecular BiologyPathologicalSpectroscopybusiness.industryOrganic Chemistryactive surveillanceProstatic NeoplasmsCancerGeneral Medicinemedicine.diseaseprostate cancerComputer Science ApplicationsChemistryUrine biomarkers030220 oncology & carcinogenesisDisease Progressionrisk predictorsbusinessBiomarkersClinical progressionInternational Journal of Molecular Sciences
researchProduct

Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cance…

2019

Abstract Background The aim of the study was to investigate the feasibility of Epidermal Growth Factor Receptor (EGFR) measurement in bladder washings of patients affected by non–muscle-invasive bladder cancer (NMIBC) and its prognostic role in identifying risk subgroups and predicting disease recurrence and progression. Patients and Methods Patients with NMIBC treated with transurethral resection of bladder tumor (TURBT) from 2012 to 2015 were enrolled. Samples of bladder washings were collected and stored at −80°C until RNA extraction. The cDNA obtained from RNA was used to perform a gene expression analysis by a real time polymerase chain reaction. Results An adequate cellular pellet was…

MaleOncologymedicine.medical_specialtyUrology030232 urology & nephrologyCystectomy03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineAdjuvant therapyHumansMedicineEpidermal growth factor receptorAgedBladder cancerBladder washingbiologybusiness.industryHazard ratioCancerBiomarkerPrognosismedicine.diseaseConfidence intervalEpidermal Growth Factor Receptor (EGFR)Up-RegulationErbB ReceptorsGene Expression Regulation NeoplasticAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsOncologyNon-Muscle Invasive Bladder Cancer (NMIBC)Chemotherapy Adjuvant030220 oncology & carcinogenesisMolecular classificationDisease Progressionbiology.proteinFeasibility StudiesBiomarker (medicine)Femalebusiness
researchProduct

Investigation of an opioid response categorization in advanced cancer patients

1999

The aim of this study was to investigate a possible distinction in three categories of opioid response and to identify possible factors associated with a poor response. A prospective survey was carried out in 105 consecutive patients requiring morphine for at least 4 weeks before death. Mean pain intensity, opioid doses and symptom intensity at weekly intervals, pain syndromes, and the presence of psychological distress were assessed. Opioid escalation index (OEI%) was calculated from the parameters recorded. Three categories were considered, including (1) patients with slow increments of opioid dose and a mean analgesic 10-cm visual analogue scale (VAS) less than 4 (responders), (2) patien…

MaleOpioid-responsivenePalliative careNauseaVisual analogue scaleAnalgesicPainNeuropathic painNeoplasmsmedicineHumansProspective StudiesCancer painProspective cohort studyGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedDose-Response Relationship DrugMorphinebusiness.industryData CollectionPsychological distrePalliative CareMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineOpioidAnesthesiaNeuropathic painDisease ProgressionFemaleNeurology (clinical)medicine.symptombusinessCancer painmedicine.drug
researchProduct

Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Surve…

2018

Hypertension is a risk factor for both progression of atrial fibrillation (AF) and development of AF-related complications, that is major adverse cardiac and cerebrovascular events (MACCE). It is unknown whether left ventricular hypertrophy (LVH) as a consequence of hypertension is also a risk factor for both these end points. We aimed to assess this in low-risk AF patients, also assessing gender-related differences. We included 799 patients from the Euro Heart Survey with nonvalvular AF and a baseline echocardiogram. Patients with and without hypertension were included. End points after 1 year were occurrence of AF progression, that is paroxysmal AF becoming persistent and/or permanent AF,…

MalePROGNOSISHypertension Left Ventricular Hypertrophy Atrial FibrillationRHYTHM-CONTROL THERAPYBlood PressureComorbidity030204 cardiovascular system & hematologyLeft ventricular hypertrophy0302 clinical medicineHeart RateRisk FactorsAtrial FibrillationRegistries030212 general & internal medicineStrokeRISKmedicine.diagnostic_testIncidencePULSE PRESSUREWOMENAtrial fibrillationMiddle AgedPulse pressureEuropeSurvival RateEchocardiographyPopulation SurveillanceHypertensionDisease ProgressionCardiologyFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicineSTROKEmedicine.medical_specialtyCANADIAN REGISTRY03 medical and health sciencesAge DistributionInternal medicinemedicineHumansCOHORTcardiovascular diseasesSex DistributionRisk factorRetrospective Studiesbusiness.industryOdds ratiomedicine.diseaseComorbidityATHEROSCLEROSISElectrocardiography AmbulatorybusinessFOLLOW-UPElectrocardiographyFollow-Up Studies
researchProduct

Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma

2014

Splenic marginal zone lymphoma (SMZL) is a mature B-cell neoplasm characterized by rather indolent clinical course. However, nearly one third of patients experience a rapidly progressive disease with a dismal outcome. Despite the characterization of clone geneticsandthe recognition of deregulated immunologic stimulation in the pathogenesis of SMZL, little is known about microenvironment dynamics and their potential biological influence on disease outcome. Here we investigate the effect of stroma-intrinsic features on SMZL disease progression by focusing on the microenvironment of the bone marrow (BM), which represents an elective disease localization endorsing diagnostic and prognostic rele…

MalePathologyBiochemistryMiceTumor MicroenvironmentMast CellMedicineMast CellsInflammation MediatorAged 80 and overMice KnockoutB-LymphocytesMice Inbred BALB CMesenchymal Stromal CellB-LymphocyteCD40 AntigenCell DifferentiationHematologyMiddle AgedPrognosismedicine.anatomical_structureDisease ProgressionCytokinesFemaleInflammation MediatorsClone (B-cell biology)HumanAdultmedicine.medical_specialtyStromal cellPrognosiCD40 LigandImmunologyDisease-Free SurvivalAnimalsHumansSplenic marginal zone lymphomaCD40 AntigensCytokineB cellAgedCell ProliferationAnimalbusiness.industryMesenchymal stem cellMesenchymal Stem CellsLymphoma B-Cell Marginal ZoneCell BiologyGenes p53medicine.diseaseLymphomaSplenic marginal zone lymphoma bone marrow microenvironment CD40Mast cell sarcomaBone marrowbusinessBlood
researchProduct

Delineating margins of lentigo maligna using a hyperspectral imaging system

2014

Lentigo maligna (LM) is an in situ form of melanoma which can progress into invasive lentigo maligna melanoma (LMM). Variations in the pigmentation and thus visibility of the tumour make assessment of lesion borders challenging. We tested hyperspectral imaging system (HIS) in in vivo preoperative delineation of LM and LMM margins. We compared lesion margins delineated by HIS with those estimated clinically, and confirmed histologically. A total of 14 LMs and 5 LMMs in 19 patients were included. HIS analysis matched the histopathological analysis in 18/19 (94.7%) cases while in 1/19 (5.3%) cases HIS showed lesion extension not confirmed by histopathology (false positives). Compared to clinic…

MalePathologySkin NeoplasmsHyperspectral imaginghyperspectral imagingSURGERYLentigo malignaHutchinson's Melanotic Freckle030207 dermatology & venereal diseases0302 clinical medicinelentigo maligna melanomaImage Processing Computer-AssistedPhotographyMelanomaAged 80 and overtumour margin assessmentMelanomaBiopsy NeedleHyperspectral imagingGeneral MedicineImmunohistochemistry3. Good healthTumour margin assessment030220 oncology & carcinogenesisDisease ProgressionFemaleRadiologylentigo malignamedicine.symptomDiagnostic Imagingmedicine.medical_specialtyDermoscopyDermatologyLentigo malignaSensitivity and SpecificitySampling StudiesDiagnosis DifferentialLesion03 medical and health sciencesMANAGEMENTmedicineHumansCONFOCAL MICROSCOPYALGORITHMLentigo maligna melanomaAgedSKIN-CANCERbusiness.industryLentigo maligna melanomaCAREmedicine.disease3121 General medicine internal medicine and other clinical medicineHistopathologybusiness
researchProduct

Lymphocytic Mitochondrial Aconitase Activity is Reduced in Alzheimer's Disease and Mild Cognitive Impairment

2015

Background: Specific mechanisms behind the role of oxidative/nitrosative stress and mitochondrial dysfunction in Alzheimer's disease (AD) pathogenesis remain elusive. Mitochondrial aconitase (ACO2) is a Krebs cycle enzyme sensitive to free radicalmediated damage. Objective: We assessed activity and expression of ACO2 extracted from blood lymphocytes of subjects with AD, mild cognitive impairment (MCI), older adults with normal cognition (OCN, age >= 65 years), and younger adults with normal cognition (YCN, age < 65 years). Plasma levels and activities of antioxidants were also measured. Methods: Blood samples were collected from 28 subjects with AD, 22 with MCI, 21 OCN, and 19 YCN. ACO2 act…

MalePathologyantioxidantAntioxidantmedicine.medical_treatmentLymphocyteMitochondrionmedicine.disease_causePolymerase Chain ReactionPathogenesisVitamin Eoxidative stressLymphocytesaconitase (aconitate hydratase)Aconitate Hydratasereactive oxygen speciesGeneral NeuroscienceACO2General MedicineAlzheimer's diseasemitochondriaPsychiatry and Mental healthClinical Psychologyantioxidantsmedicine.anatomical_structureDisease ProgressionSettore MED/26 - NeurologiaFemaleAlzheimer diseaseAlzheimer's diseaseAzheimer diseasereactive nitrogen speciemedicine.medical_specialtyaconitase (aconitate hydratase); Alzheimer disease; antioxidants; free radicals; lymphocyte; mild cognitive impairment; mitochondria; oxidative stress; reactive nitrogen species; reactive oxygen speciesBlotting Westernfree radicalslymphocytemild cognitive impairmentInternal medicinemedicineHumansCognitive DysfunctionRNA MessengerAgedfree radicaloxidative strebusiness.industryVitamin EAconitasimedicine.diseasereactive nitrogen speciesEndocrinologyGeriatrics and GerontologyAlzheimer's disease; Aconitasi; oxidative stress; Aconitase (aconitate hydratase) Azheimer disease antioxidants free radicals lymphocyte mild cognitive impairment mitochondria oxidative stress reactive nitrogen species reactive oxygen speciesMental Status SchedulebusinessBiomarkersOxidative stressJournal of Alzheimer's Disease
researchProduct